Liege, Belgium, 24 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the New Drug Application (NDA) for Estelle® has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024